UBS Starts Avadel Pharmaceuticals (AVDL) at Buy, 'Strong Lumryz growth ahead as a differentiated product in Sleep market'
Tweet Send to a Friend
(Updated - February 6, 2024 4:38 AM EST)
UBS analyst Ashwani Verma initiates coverage on Avadel Pharmaceuticals (NASDAQ: AVDL) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst Ashwani Verma initiates coverage on Avadel Pharmaceuticals (NASDAQ: AVDL) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
